NCT06707246View on ClinicalTrials.gov

A Randomized Trial Comparing the Efficacy and Safety of Secukinumab with Tofacitinib in the Treatment of Moderate to Severe Hidradenitis Suppurativa in Chinese Patients

NARecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 15, 2024

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2027

Conditions
Hidradenitis Suppurativa
Interventions
DRUG

Secukinumab 300 MG; Tofacitinib 11mg

Tofacitinib tablet 11mg per tablet; Secukinumab 150mg/ml

Trial Locations (1)

310009

RECRUITING

Jiaqi Chen, Hangzhou

All Listed Sponsors
collaborator

First Affiliated Hospital of Wenzhou Medical University

OTHER

collaborator

Jinhua Central Hospital

OTHER

collaborator

Affiliated Hospital of Jiaxing University

OTHER

collaborator

Ningbo No. 1 Hospital

OTHER

collaborator

The First People's Hospital of Huzhou

OTHER

lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER